With rare exception, all human cancers present the treating physician with therapeutic choices. Currently hundreds of drugs, combinations and targeted agents are used to treat cancer patients.
How do you as a treating physician choose?
What if you could receive specific information on how your patient’s cancer cells will react to single agents, combinations or targeted therapies?
What if there was a tool to help you significantly improve the chances of your patient’s response and survival?
Well there is.
It's called a functional profiling test and results are available within 7 days.
For 20+ years, we have refined the technology of functional profiling, a laboratory test that provides a real-time snapshot of how human tumors behave within their natural microenvironment.
Download a copy of our physician brochure here:Get the brochure
After incorporating the realization that cancer biology was predicated on cell survival and not cell growth, we redoubled our efforts to recreate the human tumor micro-environment in tissue culture. We immediately recognized that this required the preservation of cell-cell interactions found normally in the body as cellular clusters.
These cellular clusters better known as microspheroids represent cohesive populations that interact directly with stroma, vasculature, inflammatory cells, and other tumor cells. Thus, the microspheroid recapitulates the human tumor environment.
By applying cell death endpoints (the most rigorous of predictive measures) to these microspheroids, we have overcome pitfalls encountered by earlier technologies.
And, for the first time, a truly predictive human tumor model that we call the Ex Vivo Analysis of Programmed Cell Death (EVA-PCD) assay has been developed.
Below is a look at a pancreatic cancer example:
Pancreatic cancer cells isolated into microspheroids and maintained in a 3-D environment.
Whether the patient is newly diagnosed, experiencing a recurrence or their current chemotherapy is no longer effective, we can help.
Living cells vs. dead cells shows which drugs kill the cancer cells (these cells are “sensitive” to these drugs) and which ones do not (these cancer cells are “resistant” to these drugs).
The number of drugs analyzed is dependent upon the quantity/quality of the sample we receive.
We are happy to work with you to customize drug panels for each patient based on their diagnosis and previous treatment history.
The use of this assay enables you to prescribe those agents with the highest probability of improving the patient’s outcome and minimizing unnecessary toxic therapies.